Australia's most trusted
source of pharma news
Wednesday, 22 January 2025
Posted 20 January 2025 AM
CSL's Andembry has become the latest drug recommended at the PBAC's November meeting to be approved by the TGA.
The monoclonal antibody, formerly known as garadacimab, targets activated factor XII and is indicated for routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older with C1-INH HAE.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.